COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE

Edouard Louis  1     Pravin Kamble  2     Dirk Lindner  3     Christian Agboton  3    
1 CHU Liège and Liège University, Liège, Belgium
2 Takeda Pharmaceuticals Inc., Marlborough, United States
3 Takeda Pharmaceuticals, Zurich, Switzerland

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing